Latest Research And Development News

Page 1 of 115
IDT Australia expects FY27 revenue of $19 million to $20 million and EBITDA of $1 million to $1.5 million, marking a projected swing from a $0.92 million FY26 loss. The forecast rests on larger customer contracts, a five-year radiopharmaceutical deal and roughly $7 million of manufacturing upgrades.
Victor Sage
Victor Sage
18 Nov 2026
Epiminder has signed a five-year rolling partnership with Stratus Neuro to integrate its long-term Minder EEG data into StratusEEG, a cloud platform used by more than 7,000 US clinicians and administrators. The agreement gives Epiminder an established clinical workflow for its DETECT study and planned US commercialisation, although no financial terms or launch date were disclosed.
Victor Sage
Victor Sage
17 Nov 2026
TechnologyOne has delivered its 17th consecutive year of record profit, with ARR rising 18% to $652.1 million and profit before tax climbing 20% to $217.6 million. The ASX-listed ERP provider also raised its final dividend 63% as early demand for its AI products began translating into customer expansion.
Victor Sage
Victor Sage
17 Nov 2026
Dyno Nobel’s FY26 annual report shows a stronger explosives business emerging from a costly portfolio reshuffle, with EBIT up 17.4% and FY27 guidance set at A$515 million to A$555 million. The trade-off is a heavier balance sheet, a halted buyback and fresh execution risks across gas supply, defence projects and international expansion.
Victor Sage
Victor Sage
16 Nov 2026
Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
Ada Torres
Ada Torres
16 Nov 2026
Senetas says its core encryption business is gaining traction across newer markets, but the next year will test whether product growth and Thales inventory can translate into stronger earnings. The company also flagged a possible Menlo Security liquidity event, while stressing that no transaction has been announced.
Sophie Babbage
Sophie Babbage
13 Nov 2026
AdAlta has received a larger-than-expected A$1.396 million R&D Tax Incentive refund tied to overseas work on its EW-001 CAR-T therapy. The non-dilutive cash arrives before Australian manufacturing and expected FDA pre-IND meeting minutes in December.
Ada Torres
Ada Torres
12 Nov 2026
Talga’s Talnode-C natural graphite anode has performed in a KRI battery cell that reached up to 8,000 cycles while retaining 75% capacity, roughly five times the life of a conventional cell. The result opens a potential customer-qualification path in Japan, but commercial supply remains uncommitted.
Victor Sage
Victor Sage
12 Nov 2026
Anteris Technologies reported a wider third-quarter loss as spending accelerated on its PARADIGM heart-valve trial and manufacturing expansion. The company ended September with US$236.3 million in cash, but also retained unresolved weaknesses in financial reporting controls.
Ada Torres
Ada Torres
11 Nov 2026
Capability X is seeking A$12 million through a proposed ASX listing to expand its edge AI, remote operations and industrial safety business. The opportunity comes with a sharp financial caveat: FY2026 revenue fell to A$1.06 million, the company lost A$3.17 million and its auditor flagged material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
10 Nov 2026
Delorean has reached Financial Close on its $62.1 million NSW1 Horsley Park bioenergy facility, activating $30.5 million of government grants and a 25-year Brickworks gas supply agreement. Procurement can now begin, with construction targeted for early 2027, although Tanarra’s debt documentation and the project’s funding mix still warrant attention.
Victor Sage
Victor Sage
9 Nov 2026
Moderna returned to quarterly GAAP profit, raised its 2026 revenue growth outlook and reported positive Phase 3 melanoma data. The stronger quarter was supported by international COVID vaccine sales, while cash generation and pipeline execution remain important tests.
Ada Torres
Ada Torres
6 Nov 2026

Browse the archive

Full archive